Yibo Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yibo Huang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Yi Zhang
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Bin Zhang
Department of Hematology and Oncology, Northwestern University, Chicago, United States of America
1 shared publication Feng Li
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, Henan
1 shared publication- Feng Li
Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China
1 shared publication - Jin Song
Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China
1 shared publication - Jinfeng Chen
Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China; Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, China
1 shared publication
Latest Publications
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC
T cells are the most important cytotoxic cells involved in antitumor immune responses. After recognizing the major histocompatibility complex (MHC)–peptide complex, cytokines including interferon-γ (IFN-γ) are released to kill tumor cells. However, IFN-γ can also induce tumor cells to express PD-L1. This molecule can bind to PD-1 on the surface of T cells to exert inhibitory functions. In response to stimuli, like chemoradiotherapy or immunotherapy, tumor cells release damage-associated molecular patterns, including high-mobility group protein B1 (HMGB1). Our previous studies revealed that HMGB1 can increase the antitumor activity of T cells and enhance the secretion of cytokines, including IFN-γ. However, the effect of HMGB1 on PD-L1 expression in non-small cell lung cancer remains unclear. Here, we examined the expression of HMGB1 and PD-L1 in tumor tissue slices of patients with non-small cell lung cancer with high expression of IFN-γ and observed that they exhibited a negative correlation, which was also verified by our analysis in The Cancer Genome Atlas. In vitro experiments demonstrated that HMGB1 could bind to RAGE (receptor for advanced glycation end products) and inhibit IFN-γ induction of PD-L1 by inhibiting the JAK1/STAT3 pathway. In vitro and in vivo experiments indicated that HMGB1 enhanced the antitumor effects of chimeric antigen receptor T cells and inhibited tumor growth. These results showed that HMGB1 inhibited IFN-γ–induced PD-L1 expression, thereby enhancing the antitumor effects of T cells, and confirmed the role of HMGB1 as a prognostic indicator for lung cancer treated with chimeric antigen receptor T cells.
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC
T cells are the most important cytotoxic cells involved in antitumor immune responses. After recognizing the major histocompatibility complex (MHC)–peptide complex, cytokines including interferon-γ (IFN-γ) are released to kill tumor cells. However, IFN-γ can also induce tumor cells to express PD-L1. This molecule can bind to PD-1 on the surface of T cells to exert inhibitory functions. In response to stimuli, like chemoradiotherapy or immunotherapy, tumor cells release damage-associated molecular patterns, including high-mobility group protein B1 (HMGB1). Our previous studies revealed that HMGB1 can increase the antitumor activity of T cells and enhance the secretion of cytokines, including IFN-γ. However, the effect of HMGB1 on PD-L1 expression in non-small cell lung cancer remains unclear. Here, we examined the expression of HMGB1 and PD-L1 in tumor tissue slices of patients with non-small cell lung cancer with high expression of IFN-γ and observed that they exhibited a negative correlation, which was also verified by our analysis in The Cancer Genome Atlas. In vitro experiments demonstrated that HMGB1 could bind to RAGE (receptor for advanced glycation end products) and inhibit IFN-γ induction of PD-L1 by inhibiting the JAK1/STAT3 pathway. In vitro and in vivo experiments indicated that HMGB1 enhanced the antitumor effects of chimeric antigen receptor T cells and inhibited tumor growth. These results showed that HMGB1 inhibited IFN-γ–induced PD-L1 expression, thereby enhancing the antitumor effects of T cells, and confirmed the role of HMGB1 as a prognostic indicator for lung cancer treated with chimeric antigen receptor T cells.
- 25 June 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217849
The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications
- 25 June 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217849
The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications